Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Tikcro Technologies Announces 2016 Annual General Meeting

Tikcro Technologies
Posted on: 24 Nov 16

TEL AVIV, Israel, Nov. 23, 2016 /PRNewswire/ -- Tikcro Technologies Ltd. (OTCQX: TIKRF) today announced that its Annual General Meeting of Shareholders will be held on December 28, 2016 at 10:30 a.m. Israel time, at the office of the Company at 7 Sapir Street, Ness Ziona, Israel.

The agenda of the meeting is as follows:

(1)   election of Eric Paneth and Izhak Tamir to the Board of Directors;

(2)   re-approval of the existing compensation policy for officers and directors for a period of three years;

(3)   reappointment of Kost Forer Gabbay and Kasierer, a member of Ernst & Young Global, as independent auditors; and

(4)   consideration of audited financial statements for the year ended December 31, 2015.

Items 1 and 3 require the approval of a simple majority of the shares voted on the matter. Item 2 requires the affirmative vote of a majority of the shares present, in person or by proxy, and voting on the matter, provided that either (i) at least a majority of the shares of non-controlling shareholders and shareholders who do not have a personal interest in the resolution are voted in favor of the proposal, or (ii) the total number of shares of non-controlling shareholders and of shareholders who do not have a personal interest in the resolution voted against the proposal does not exceed two percent of the outstanding voting power in the Company. Item 4 will not involve a vote of the shareholders.

The record date for the meeting is November 28, 2016. Tikcro will send its shareholders of record a proxy statement describing the various matters to be voted upon at the meeting, along with a proxy card enabling them to indicate their vote on each matter.

About Tikcro Technologies:

Tikcro Technologies Ltd. (OTCQX: TIKRF) supports early stage development in growth areas, with a focus on biotechnology projects originated in Israeli academic centers. Tikcro is engaged with development of certain antibodies selected and verified in pre-clinical trials with a focus on antibodies binding to cancer immune modulators. For more information about Tikcro, visit Tikcro's website at

Editor's Details

Mike Wood

Last updated on: 24/11/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.